XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2023
May 17, 2022
Dec. 20, 2018
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Interest income       $ 261,269 $ 60,271 $ 444,685 $ 125,098  
Outstanding principal balance       889,110   889,110   $ 2,158,417
Accrued interest       48,900   48,900   275,547
Accounts receivable - related party       23,568,130   23,568,130   22,761,990
Prepaid expenses and other current assets - related party       4,370,231   4,370,231   1,967,527
Revenue       12,363,429 13,208,504 24,713,206 26,280,304  
Grigorios Siokas [Member]                
Borrowing     $ 1,718,400          
Outstanding principal balance       13,087   13,087   12,821
Foreign curreny translation       209   266    
Accrued interest       973   973   206,355
Interest rate     4.70%          
Maturity date     Mar. 18, 2019          
Cana Holdings Laboratories Holding Limited [Member]                
Secured promissory note $ 4,457,520              
Description related to interest on principal Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.18% as of June 30, 2023).              
Maturity of promissory note 5 years              
Interest income $ 148,789     112,292        
DOC Pharma S.A. [Member]                
Interest income           118,245    
Prepaid expenses           $ 7,599,545    
Interest rate           5.50%    
Loan term           10 years    
Maturity date           Dec. 01, 2032    
Accounts payable and accrued expenses - related party       2,095   $ 2,095   201,991
Prepaid balance       4,279,200   4,279,200    
Accounts receivable - related party       1,517,092   1,517,092   2,070,570
Prepaid expenses and other current assets - related party       5,664,993   5,664,993   3,320,345
Revenue       2,120 34,132 $ 2,767 418,717  
Agreement term           5 years    
Pieces per product           1,000 pieces    
Loan current portion       473,200   $ 473,200   427,720
Loan non-current portion       3,712,800   3,712,800   3,851,280
Inventroy purchase       193,831 624,627 607,984 1,328,435  
Purchase of branded pharmaceuticals $ 1,965,600              
Description of research and development   The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022            
Monthly basis instalments           35,660    
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]                
Inventroy purchase       190,021 604,549 593,427 872,489  
Dimitrios Goulielmos [Member]                
Outstanding principal balance       11,138   11,138   10,912
Foreign curreny translation       177   226    
Panagiotis Kozaris [Member]                
Shares owned           51,159 0  
Prepaid expenses       194,215   194,215   143,056
Maria Kozari [Member]                
Accounts receivable - related party       956,051   956,051   760,025
Net sales       117,219 $ 130,233 236,205 $ 261,746  
George Terzis [Member]                
Unpaid salaries and bonuses       70,000   70,000    
Kanarogloy & Sia Epe [Member]                
Accounts payable and accrued expenses - related party       6,526   6,526   $ 12,306
due to related party       $ 1,244   $ 1,244